1 |
Fisher B, Bauer M, Wickerham DL (1983). Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer, 52, 1551-7.
DOI
|
2 |
Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN (2013). Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat, 78, 105-18.
|
3 |
Omidvari S, Hamedi SH, Mohammadianpanah M, et al (2013). Very late relapse in breast cancer survivors: a report of 6 cases. Iran J Cancer Prev, 6, 113-7.
|
4 |
Oven Ustaalioglu BB, Balvan O, Bilici A, et al (2015). The differences of clinicopathological factors for breast cancer in respect to time of recurrence and effect on recurrence-free survival. Clin Transl Oncol, [Epub ahead of print]
|
5 |
Payandeh M, Malayeri R, Sadeghi M, Sadeghi E, Gholami F (2015). Expression of p53 and Ki67 in the patients with triple negative BC and invasive ductal carcinoma. Am J Cancer Prev, 3, 58-61.
|
6 |
Payandeh M, Shazad B, Sadeghi M, Bahari B, Sadeghi E (2015). Association between of BMI and blood groups with breast cancer incidence among women of West Iran: a case-control study. Am J Cancer Prev, 3, 65-7.
|
7 |
Perez-Rivas LG, Jerez JM, Carmona R, et al (2014). A microRNA signature associated with early recurrence in breast cancer. PLoS One, 9, 91884.
DOI
|
8 |
Saxe GA, Rock CL, Wicha MS, Schottenfeld D (1999). Diet and risk for breast cancer recurrence and survival. Breast Cancer Res Treat, 53, 41-53.
DOI
|
9 |
Sestak I, Cuzick J (2015). Markers for the identification of late breast cancer recurrence. Breast Cancer Res, 17, 10.
DOI
|
10 |
Shafiee SM, Rasti M, Seghatoleslam A, Azimi T, Owji AA (2015). UBE2Q1 in a human breast carcinoma cell line: overexpression and interaction with p53. Asian Pac J Cancer Prev, 16, 3723-7.
DOI
|
11 |
Stankov A, Bargallo-Rocha JE, Silvio AN, et al (2012). Prognostic factors and recurrence in breast cancer: experience at the national cancer institute of Mexico. ISRN Oncol, 2012, 825258.
|
12 |
Thurlimann B (2007). Reducing the risk of early recurrence in hormone-responsive breast cancer. Ann Oncol, 18, viii8-17.
|
13 |
Wang WJ, Lei YY, Mei JH, Wang CL (2015). Recent progress in HER2 associated breast cancer. Asian Pac J Cancer Prev, 16, 2591-600.
DOI
|
14 |
Yin W, Di G, Zhou L, et al (2009). Timevarying pattern of recurrence risk for Chinese breast cancer patients. Breast Cancer Res Treat, 114, 527-35.
DOI
|
15 |
Carter CL, Allen C, Henson DE (1989). Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer, 63, 181-7.
DOI
|
16 |
Ahn SG, Lee HM, Cho SH, et al (2013). The difference in prognostic factors between early recurrence and late recurrence in estrogen receptor-positive breast cancer: nodal stage differently impacts early and late recurrence. PLoS One, 8, 63510.
DOI
|
17 |
Bogina G, Lunardi G, Coati F, et al (2015). Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence. Tumori, [Epub ahead of print].
|
18 |
Boyages J, Recht A, Connolly JL, et al (1990). Early breast cancer: predictors of breast recurrence for patients treated with conservative surgery and radiation therapy. Radiother Oncol, 19, 29-41.
DOI
|
19 |
Davies C, Godwin J, Gray R, et al (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials. Lancet, 378, 771-84.
DOI
ScienceOn
|
20 |
Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G (1996). Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat, 41, 177-85.
DOI
|
21 |
Diaconu C, Chifu C, Cosman C, et al (2010). Early recurrence in favorable stage II breast cancer-which approach is the best? Rev Med Chir Soc Med Nat Iasi, 114, 771-6.
|
22 |
Doussal VLe, Tubiana-Hulin M, Friedman S, et al (1989). Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer, 64, 1914-21.
DOI
|